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Guillain-Barré syndrome (GBS) is the most common
cause of acute flaccid paralysis in polio-free regions.
Considerable evidence links Campylobacter infection with
GBS, but evidence that implicates other pathogens as trig-
gers remains scarce. We conducted a time-series analysis
to investigate short-term correlations between weekly labo-
ratory-confirmed reports of putative triggering pathogens
and weekly hospitalizations for GBS in England from 1993
through 2002. We found a positive association between the
numbers of reports of laboratory-confirmed influenza A in
any given week and GBS hospitalizations in the same
week. Different pathogens may trigger GBS in persons of
different ages; among those <35 years, numbers of weekly
GBS hospitalizations were associated with weekly
Campylobacter and  Mycoplasma pneumoniae reports,
whereas among those >35 years, positive associations
were with influenza. Further studies should estimate the
relative contribution of different pathogens to GBS inci-
dence, overall and by age group, and determine whether
influenza is a real trigger for GBS or a marker for influenza
vaccination.
G
uillain-Barré syndrome (GBS) is the most common
cause of acute flaccid paralysis in polio-free regions.
Estimated incidence in high-income countries is 0.4–4.0
cases per 100,000 population (1). Campylobacter jejuni is
the most commonly identified infectious trigger for GBS.
Several studies have demonstrated evidence of recent C.
jejuni infection in a higher proportion of GBS case-
patients than in controls (2–10). Other pathogens, includ-
ing cytomegalovirus (7), Epstein-Barr virus (7),
Haemophilus influenzae (11–14), and Mycoplasma pneu-
moniae (7,15,16), have been suggested as possible GBS
triggers, as was influenza vaccination in the United States
during 1976–1977 (17). However, epidemiologic evidence
that implicates these latter agents remains scarce. We con-
ducted a time-series analysis to investigate temporal asso-
ciations between weekly variations in reports of
microbiologically confirmed infections and hospital
admissions for GBS.
Methods
Reports of Microbiologically Confirmed Infections
Positive microbiologic diagnoses ascertained through
voluntary laboratory reporting in England and Wales are
recorded in the national infections database (LabBase2)
(18). We obtained weekly reports of infections suspected
of causing GBS, namely, Campylobacter spp.,
cytomegalovirus, Epstein-Barr virus, Haemophilus
influenzae (B and non-B), Mycoplasma pneumoniae, and
influenza (A, B, and all influenza) from 1993 through
2002. Influenza vaccination figures are available only
quarterly and do not provide sufficient temporal resolution
for this analysis.
We used the specimen date for all analyses because
onset dates were rarely available. For Campylobacter, the
median delay between patients’ onset date and the speci-
men date was 4 days (interquartile range 3–7 days); for
90% of cases, the delay was <14 days (19). Similar data
were unavailable for other pathogens.
GBS Hospitalizations
Nonidentifiable GBS hospitalization data were provid-
ed by Hospital Episodes Statistics (HES) (20), which
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Health Service hospitals. An episode is a continuous peri-
od of treatment under 1 consultant. Each episode includes
patient’s age, sex, admission date, episode duration,
episode number, and <14 possible International
Classification of Diseases (ICD) diagnoses. Because a
patient may see several consultants during a hospital stay,
several episodes for the same hospitalization event may
appear in HES records. Since April 1997 a unique code
identifies episodes for the same patient. Aseries of contin-
uous episodes constitutes a spell of treatment. This method
of episode linkage was applied to records from January
1998 onward. Before then, only episodes classified as first
episodes were used to avoid including multiple episodes
for the same patient spell.
A GBS admission was defined as a spell with GBS-
related ICD codes (ICD-9 357.0/ICD-10 G61.0) in any of
the first 3 diagnostic codes. From 1998 through 2002,
3,477 repeat spells were excluded; these are unlikely to
represent independent events, e.g., the likelihood of recur-
rent GBS may depend on host genetic factors.
The 2 series of hospitalizations (1993–1997 and
1998–2002) were collapsed into weekly counts of GBS
admissions. For 1993, data were only available from April
1 on. We compared the 2 periods to investigate whether
inability to exclude repeat spells from 1993 through 1997
affected the seasonal pattern of GBS admissions. No major
differences were seen (Figure 1), and the 2 periods were
combined into a weekly time-series of 10 years.
Statistical Analysis
We aimed to answer the following question: Is an
increase in the number of laboratory reports in any given
week associated with increases in GBS hospitalizations in
subsequent weeks? In choosing appropriate statistical
methods, special characteristics of time-series data must be
considered. Such data exhibit nonrandom patterns over
time. These include long-term increasing or decreasing
trends (whereby weekly GBS hospitalizations within a year
are more closely related than between years) and seasonal
patterns (whereby the number of GBS hospitalizations in
any given week is similar to that in the same week for other
years). In addition, weekly hospitalizations are count data,
following a Poisson rather than a normal distribution. 
For these reasons, time-series observations cannot be
considered to be independent, and statistical techniques
commonly used for independent, normally distributed data
(such as simple correlation) are inappropriate. Special
methods that account for temporal dependence in the data
are needed. Specifically, temporal dependence in time-
series data can result in confounding due to long-term
trends (year-on-year) and seasonal (within-year) patterns.
Two variables could apparently be related in time because
they have similar seasonal characteristics, not because one
causes the other. For example, bottled water consumption
increases in summer, when the incidence of salmonellosis
is highest. This does not imply that bottled water is a risk
factor for Salmonella infection; rather, bottled water con-
sumption is influenced by ambient temperature, which
itself independently influences Salmonella transmission.
The exposure-outcome association could also be con-
founded or obscured by other time-varying factors. For
example, if influenza causes GBS, GBS admissions should
increase in winter, when influenza incidence is highest.
However, Campylobacter has the opposite seasonality; if
Campylobacter is also associated with GBS, high numbers
of GBS admissions could still occur when influenza
reports are low, because these GBS cases are due to
Campylobacter (or other pathogens with different season-
ality). Time-series methods account for such temporal
dependencies in data by adjusting for these long-term
trends and seasonal patterns, which enables associations to
be investigated over shorter periods, independent of trend
and seasonal components.
We used multivariable Poisson regression adapted for
time-series data (21–23) to investigate the effect of week-
ly variations in reports of different pathogens on the num-
ber of GBS hospitalizations; we adjusted for long-term
trends and seasonality. The weekly number of GBS hospi-
talizations was the outcome, and the weekly number of
reports for each pathogen was the exposure. We assumed a
log-linear relationship between exposure and outcome,
i.e., that an increase in the number of reports of a particu-
lar pathogen resulted in a constant increase in the log num-
ber of GBS hospitalizations throughout the range of
laboratory reports. 
We adjusted for long-term (year-on-year) trends by
including a variable indicating the year of hospitalization
in the regression model; thus, we allowed the mean num-
ber of GBS hospitalizations to vary between years. We
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Figure 1. Seasonal distribution of Guillain-Barré syndrome admis-
sions during 1993–1997 and 1998–2002.controlled for seasonality by using Fourier terms (21,24).
Fourier terms can be used to produce a smooth function of
expected values for any set of periodic data (e.g., a season-
al pattern). This is achieved by introducing into the regres-
sion model a linear combination of pairs of sine and cosine
terms (harmonics) of varying wavelengths. A harmonic is
an integer fraction of 1 full wavelength (here, 1 year). The
more harmonics used, the better the fit to the hospitaliza-
tion series (i.e., the greater the level of seasonal adjust-
ment). A seasonal pattern with a single peak and single
trough within 1 year could be reproduced with 1 harmon-
ic. In reality, seasonal patterns are more complex, and sev-
eral harmonic terms are required for adequate seasonal
adjustment. Given sufficient seasonal adjustment, all vari-
ation in the hospitalization series explained by seasonality
is removed; any remaining variation must be due to other
factors or random noise. This residual variation, independ-
ent of long-term trends and seasonal patterns, and its asso-
ciation with weekly reports of infections was our focus of
interest. We used 6 harmonics to adjust for periodic pat-
terns in the data >2 months, assuming that GBS risk is
increased for <2 months after infection. In addition, we
introduced a variable that indicated weeks in which public
holidays occurred, to adjust for artifactual variation in lab-
oratory reporting and hospitalizations during these weeks.
Lag Effects
Because of the time lag between infection and GBS, the
number of GBS admissions is likely to be associated not
with the number of laboratory reports in the same week,
but with the number of reports some time before. We thus
performed separate regressions with exposure variables
lagged by <8 weeks. Further, because of delays in seeking
healthcare, diagnosing infection, and reporting positive
diagnoses to national surveillance, increases in hospitaliza-
tions could precede increases in laboratory reports. To
account for this possibility, we also performed regressions
of GBS admissions against laboratory reports within the
subsequent 4 weeks.
The core models thus contained the logged GBS hospi-
talization series as the dependent variable, indicator vari-
ables for year, Fourier terms for season, and an indicator
variable for weeks with public holidays. The weekly num-
ber of reports of a particular pathogen, either in the same
week or lagged by a certain number of weeks, was then
introduced as the explanatory variable of interest. The
regression equation for the models predicting the expecta-
tion of the logarithm of weekly GBS hospitalizations, Y,
was
where δy represents the coefficients for each year (y), S(t)
represents a smooth function of season (comprising 6 har-
monics), and φ (holiday) is a term representing weeks with
public holidays. The regression coefficient, β, is the effect
of the exposure of interest (the weekly number of labora-
tory reports, X). Its exponential, the relative risk (RR),
reflects the ratio increase in GBS hospitalizations per unit
increase in laboratory reports of pathogen (p) at lag t-l,
where l ranges from 8 weeks before to 4 weeks after the
GBS hospitalization.
We fit separate models for each pathogen at each lag.
We assessed model fit by looking at residual variation. We
used the partial autocorrelation function (25) to investigate
the presence of residual autocorrelation, i.e., whether
residual variation in GBS hospitalizations in any given
week was correlated with residual variation in other
weeks. Some degree of autocorrelation at a lag of 1 week
remained after adjustment for yearly and seasonal patterns.
We controlled for this by adding to all models a term for
the residuals lagged by 1 week (a first-order autoregressive
term; AR1 in the equation). The scale parameter for stan-
dard errors was set as the Pearson χ2 statistic divided by
the residual degrees of freedom to allow for possible
overdispersion in the data.
Age Group Analysis
Associations between GBS and infection could differ
between age groups; an association between a pathogen
and GBS might only become apparent in a limited age
range. We performed subanalyses to investigate associa-
tions in different age groups. Because the age distribution
of GBS case-patients is not uniform, we categorized age
into 3 broad groups: <35 years, 35–64 years, and >65
years, according to the age distribution of GBS patient
admissions (Figure 2). Age group–specific models were fit
similarly to those for all ages.
All lags at which positive associations were found are
presented. However, because of the large number of statis-
tical tests performed (13 lags per pathogen per age group),
a positive association at a given lag was considered poten-
tially relevant only if it occurred within a cluster. A cluster
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Figure 2. Age distribution of first hospitalization for Guillain-Barré
syndrome, England, April 1993–December 2002. was defined as 2 or more consecutive lags, each associat-
ed with the outcome at the 0.05 significance level. This
approach reduces the probability of observing chance
associations due to multiple testing. Within clusters, lags
significant at the 0.01 level were considered important.
The adjusted coefficient from these models was used to
calculate the expected increase in GBS admissions per
10% increase in the range of laboratory reports at a given
lag. All statistical analyses were performed in Stata 8.0
(Stata Corp., College Station, TX, USA).
Results
In the 10-year study period, 11,019 primary admissions
for GBS occurred: 2,929 (26.6%) patients were <35 years
of age, 4,467 (40.5%) were ages 35–64 years, and 3,623
(32.9%) were >65 years. Summary statistics for the week-
ly number of GBS admissions and laboratory reports for
the different pathogens are found in Table 1.
Table 2 gives details of the lags for each pathogen for
which significant associations with GBS admissions were
found. Only clusters of lags that were significant at the
0.05 significance level are presented. Within clusters, lags
that were significant at the 0.01 significance level appear
in bold. For example, for influenza reports in all ages, sig-
nificant associations were found between the number of
GBS hospitalizations in any given week and the number
of influenza reports in the same week (lag 0) and the pre-
vious week (lag 1); the p value for the coefficient at lag 0
was <0.01. Lags that were associated with GBS at the
0.05 significance level but did not occur in clusters are
shown in Table 3. Seventeen such lags occurred, consis-
tent with 1 in 20 tests giving a significant result by chance
(at p<0.05) (given 312 combinations of pathogens, age
groups, and lags).
Table 4 presents RRs and 99% confidence intervals
(CIs) for the associations shown in Table 2. Only those
individual lags from Table 2 that were significant at the
0.01 level of precision are presented. The RRs represent
the relative increase in GBS admissions per 10% increase
in the range of laboratory reports for a given pathogen at a
given lag. For example, for influenza A, the maximum
number of laboratory reports in any given week was 398,
while the minimum was zero; an increase in influenza A
reports of 39.8 (10% of the range) in any given week
results, on average, in a 1.03-fold (or 3%) higher incidence
of GBS admissions in the same week (RR = 1.032, 99% CI
1.008–1.057). Overall, a positive association was found
only with influenza and influenza A at a lag of zero weeks
(in the same week as GBS admission).
Different pathogens are associated with GBS admission
in different age groups. In those <35 years, the number of
GBS admissions in a given week was associated with the
number of Campylobacter spp. reports 5 and 4 weeks ear-
lier and with the number of M. pneumoniae reports in the
same week and 1 and 3 weeks later.
Among persons ages 35–64 years, a positive associa-
tion was found between the number of GBS admissions in
any given week and the number of all influenza reports 1
and 2 weeks earlier. In those ages >65 years, associations
were found between the number of GBS admissions and
the number of all influenza and influenza A reports in the
current week and 1 week before hospitalization.
The results were robust to varying degrees of seasonal
adjustment; we repeated the analysis and adjusted for sea-
sonal wavelengths of up to 4 months (3 harmonics) and 1
month (12 harmonics) and used indicator variables for
month as well, all with similar results. Table 5 shows those
lags that consistently appeared in clusters at all levels of
seasonal adjustment. Results for influenza and M. pneumo-
niae were not sensitive to the degree of seasonal adjust-
ment. For Campylobacter, clusters of lags were seen with
all Fourier models, but not with models that used month
indicators.
Guillain-Barré Syndrome, England
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 12, December 2006 1883Discussion
We found associations between the weekly number of
laboratory reports of various pathogens and incidence of
GBS hospitalizations. Different organisms may be respon-
sible for triggering GBS in different age groups. In partic-
ular,  Campylobacter and  M. pneumoniae appear to be
associated with GBS in those <35 years, while influenza
associations were seen in those >35 years. Differences in
the pathogens responsible for triggering GBS in different
age groups have not previously been reported.
No clusters of significant lags were found for
cytomegalovirus, Epstein-Barr virus, and H. influenzae
infections. This could be due to low statistical power (on
average, <10 reports per week were made for Epstein-Barr
virus and H. influenzae), or it could indicate a very small
risk or none after these infections.
Our results are subject to several limitations. HES data
exclude information from private hospitals. Given the uni-
versality of healthcare in England, however, the proportion
of GBS cases diagnosed in private hospitals is likely to be
small. Although we used only ICD codes specific for GBS,
some GBS cases may be classified under nonspecific
codes, namely, ICD-9 357.9 (unspecified toxic and inflam-
matory neuropathy) and ICD-10 G61.9 (inflammatory
polyneuropathy unspecified). However, these codes
include a large proportion of cases unrelated to GBS; their
inclusion in the analysis would dilute any associations with
the infections investigated. Misdiagnosis of GBS is also
possible; a proportion of GBS diagnoses is likely to repre-
sent false positives. We could not validate diagnoses
through hospital chart review because identities were hid-
den in the HES data, and we did not have access to
patients’ records. However, any misclassification arising
from inclusion of false-positive GBS diagnoses will be
nondifferential, i.e., the likelihood of misdiagnosis with
GBS is unrelated to the likelihood of diagnosis with the
pathogens investigated. Inclusion of non-GBS cases could
have resulted in effect dilution, but this inclusion would
likely not have yielded positive associations when none
truly existed.
Laboratory reports for any condition represent only a
subset of all symptomatic cases of disease in the com-
munity. Our analysis assumes that, for a given condition,
the seasonal pattern of laboratory reports accurately reflects
the pattern of all community cases. Ascertainment of
influenza is likely to be more comprehensive in winter
because microbiologic investigation for this pathogen is not
routinely conducted outside the influenza season (26). This
could affect our ability to detect associations in different
seasons, but this was not the focus of our study. Our analy-
sis also assumes that the seasonal pattern of laboratory
reports is accurately reflected within each age group. This
may not be true if, for example, younger persons are less
likely to visit the health services (and, thus, be included in
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influenza season. However, laboratory report data for
influenza show a distinct and consistent peak during the
winter months in all age groups (data not shown).
Among Campylobacter spp., only C. jejuni is thought
to cause GBS. As clinical isolates of Campylobacter are
not routinely speciated in England and Wales, non-jejuni
species could not be excluded from the analysis. However,
the England and Wales Campylobacter Sentinel
Surveillance Scheme indicates that 80%–90% of reports of
Campylobacter infection are due to C. jejuni (19); inclu-
sion of species not linked to GBS would attenuate rather
than inflate any effect on GBS admissions.
The regression coefficients indicate associations
between the incidence of various pathogens and GBS
admissions, but the coefficients themselves are not directly
comparable between pathogens. This is because their mag-
nitude is dependent not only on the true magnitude of the
association, but also on the proportion of all cases that is
captured by laboratory reports, and this will vary by
pathogen (for example, severe conditions are more likely to
be reported). Thus, estimates of the relative incidence of
GBS due to the different pathogens cannot be obtained
from these data. In addition, some evidence exists, particu-
larly for C. jejuni, that GBS can develop after subclinical
infection. Our analysis did not include asymptomatic infec-
tions, so our results apply only to clinical cases of infection.
These findings nevertheless raise hypotheses that merit fur-
ther investigation. For example, several case reports and
immunologic analyses have suggested a link between M.
pneumoniae infection and GBS (7,15,16), but such a link
has not been confirmed by robust epidemiologic studies.
Our results suggest that studies focusing on younger GBS
patients could help clarify any such association.
Whether the associations with influenza are real or
whether they reflect seasonal patterns in influenza vaccina-
tion is unclear. Influenza vaccination has previously been
linked to GBS. During the mass vaccination campaign
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1976–1977, GBS incidence among vaccinees was 7-fold
higher in the 6 weeks after vaccination than in nonvacci-
nees (17,26). Similar analyses during subsequent influen-
za seasons (with no mass vaccination) have found no
increased risk (27), or a doubling of the risk (28), which
suggests that differences in antigenic formulation or char-
acteristics of vaccinated populations are influential factors
in vaccine-related GBS risk. Here, we found associations
with influenza A only; this may reflect the antigenic com-
position of influenza vaccines, or differential risk resulting
from antigenic differences between subtype A and B
strains of influenza.
The short lags identified here between increases in
influenza reports and subsequent GBS admissions are con-
sistent with a vaccine trigger; the risk period for vaccine-
related GBS is believed to be 6 weeks, and increases in
vaccination coverage would be expected to precede sea-
sonal rises in influenza. Vaccination could also explain the
lack of an association in younger persons, because influen-
za vaccination is not generally recommended in healthy
persons <65 years in the United Kingdom. Influenza vac-
cine coverage data indicate that for the study period, vac-
cine uptake was <1% in low-risk groups ages <35 years,
<10% among those ages 35–54 years, and 20%–30%
among those ages >65 years (29). For elderly persons at
high risk, uptake increased from 40% to 65% from 1993
through 2002 (30). These data support the hypothesis that
persons in older age groups have a greater vaccine-induced
risk of GBS, although a true association with the disease of
influenza is still possible. Primary care–based studies
investigating the influenza and influenza vaccination sta-
tus of GBS patients could help resolve this issue.
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